Assessing the radiation response of lung cancer with different gene mutations using genetically engineered mice.
Date
2013
Journal Title
Journal ISSN
Volume Title
Citation Stats
Attention Stats
Abstract
PURPOSE: Non-small cell lung cancers (NSCLC) are a heterogeneous group of carcinomas harboring a variety of different gene mutations. We have utilized two distinct genetically engineered mouse models of human NSCLC (adenocarcinoma) to investigate how genetic factors within tumor parenchymal cells influence the in vivo tumor growth delay after one or two fractions of radiation therapy (RT). MATERIALS AND METHODS: Primary lung adenocarcinomas were generated in vivo in mice by intranasal delivery of an adenovirus expressing Cre-recombinase. Lung cancers expressed oncogenic Kras(G12D) and were also deficient in one of two tumor suppressor genes: p53 or Ink4a/ARF. Mice received no radiation treatment or whole lung irradiation in a single fraction (11.6 Gy) or in two 7.3 Gy fractions (14.6 Gy total) separated by 24 h. In each case, the biologically effective dose (BED) equaled 25 Gy10. Response to RT was assessed by micro-CT 2 weeks after treatment. Quantitative reverse transcription-polymerase chain reaction (qRT-PCR) and immunohistochemical staining were performed to assess the integrity of the p53 pathway, the G1 cell-cycle checkpoint, and apoptosis. RESULTS: Tumor growth rates prior to RT were similar for the two genetic variants of lung adenocarcinoma. Lung cancers with wild-type (WT) p53 (LSL-Kras; Ink4a/ARF(FL/FL) mice) responded better to two daily fractions of 7.3 Gy compared to a single fraction of 11.6 Gy (P = 0.002). There was no statistically significant difference in the response of lung cancers deficient in p53 (LSL-Kras; p53(FL/FL) mice) to a single fraction (11.6 Gy) compared to 7.3 Gy × 2 (P = 0.23). Expression of the p53 target genes p21 and PUMA were higher and bromodeoxyuridine uptake was lower after RT in tumors with WT p53. CONCLUSION: Using an in vivo model of malignant lung cancer in mice, we demonstrate that the response of primary lung cancers to one or two fractions of RT can be influenced by specific gene mutations.
Type
Department
Description
Provenance
Subjects
Citation
Permalink
Published Version (Please cite this version)
Publication Info
Perez, Bradford A, A Paiman Ghafoori, Chang-Lung Lee, Samuel M Johnston, Yifan Li, Jacob G Moroshek, Yan Ma, Sayan Mukherjee, et al. (2013). Assessing the radiation response of lung cancer with different gene mutations using genetically engineered mice. Front Oncol, 3. p. 72. 10.3389/fonc.2013.00072 Retrieved from https://hdl.handle.net/10161/16172.
This is constructed from limited available data and may be imprecise. To cite this article, please review & use the official citation provided by the journal.
Collections
Scholars@Duke
Chang Lung Lee
The overall goal of the Lee lab is to improve the therapeutic window of radiation therapy and the survivorship of cancer patients by minimizing the acute and late effects of radiation. The lab studies mechanisms underlying radiation-induced tissue injury and regeneration to develop novel medical countermeasures and predictive biomarkers. The Lee lab is supported by active NIH grants studying radiation-induced oral mucositis (R01DE033404), gastrointestinal acute radiation syndrome (U01AI186969 and R21AI193496), radiation-induced intestinal fibrosis (U01AI183940), and radiation-induced heart disease (U01AI189426).
Cristian Tudorel Badea
- Our QIAL lab advances quantitative imaging by designing novel CT systems, reconstruction algorithms, image analysis and applications, with a core strength in preclinical CT.
- Current efforts center on spectral CT (dual-energy and photon-counting) with nanoparticle contrast agents for theranostics, multidimensional CT for challenging applications such as intracranial aneurysm, cardiac, and perfusion imaging, and modern reconstruction and image processing ( including deep learning).
- In parallel, we lead co-clinical cancer imaging work; I served as PI of the U24 Duke Preclinical Research Resources for Quantitative Imaging Biomarkers within the NCI Co-Clinical Imaging Research Program (CIRP).
- We are also building a virtual preclinical photon-counting CT platform for cancer studies to accelerate method development and translation.
Unless otherwise indicated, scholarly articles published by Duke faculty members are made available here with a CC-BY-NC (Creative Commons Attribution Non-Commercial) license, as enabled by the Duke Open Access Policy. If you wish to use the materials in ways not already permitted under CC-BY-NC, please consult the copyright owner. Other materials are made available here through the author’s grant of a non-exclusive license to make their work openly accessible.
